Results 41 to 50 of about 100,338 (264)

Natural Proline-Rich Cyclopolypeptides from Marine Organisms: Chemistry, Synthetic Methodologies and Biological Status

Marine Drugs, 2016
Peptides have gained increased interest as therapeutics during recent years. More than 60 peptide drugs have reached the market for the benefit of patients and several hundreds of novel therapeutic peptides are in preclinical and clinical development ...
Wan-Yin Fang, Rajiv Dahiya, Hua-Li Qin, Rita Mourya, Sandeep Maharaj   +4 more
doaj   +1 more source

Software-aided detection and structural characterization of cyclic peptide metabolites in biological matrix by high-resolution mass spectrometry

Journal of Pharmaceutical Analysis, 2020
Compared to their linear counterparts, cyclic peptides show better biological activities, such as antibacterial, immunosuppressive, and anti-tumor activities, and pharmaceutical properties due to their conformational rigidity.
Ming Yao, Tingting Cai, Eva Duchoslav, Li Ma, Xu Guo, Mingshe Zhu   +5 more
doaj   +1 more source

mMass as a software tool for the annotation of cyclic peptide tandem mass spectra. [PDF]

PLoS ONE, 2012
Natural or synthetic cyclic peptides often possess pronounced bioactivity. Their mass spectrometric characterization is difficult due to the predominant occurrence of non-proteinogenic monomers and the complex fragmentation patterns observed. Even though
Timo H J Niedermeyer, Martin Strohalm
doaj   +1 more source

Methionine epimerization in cyclic peptides

RSC Advances, 2021
One step regioselective methionine epimerization in cyclic peptides followed by selective functionalization leads to chemical novelty.
Pramodkumar D. Jadhav, Jianheng Shen, Peta-Gaye Burnett, Jian Yang, Ramaswami Sammynaiken, Martin J. T. Reaney   +5 more
openaire   +3 more sources

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

MultiCycPermea: accurate and interpretable prediction of cyclic peptide permeability using a multimodal image-sequence model

BMC Biology
Background Cyclic peptides, known for their high binding affinity and low toxicity, show potential as innovative drugs for targeting “undruggable” proteins. However, their therapeutic efficacy is often hindered by poor membrane permeability.
Zixu Wang, Yangyang Chen, Yifan Shang, Xiulong Yang, Wenqiong Pan, Xiucai Ye, Tetsuya Sakurai, Xiangxiang Zeng   +7 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Binding Interactions of Peptide Aptamers

Molecules, 2020
Peptide aptamers are short amino acid chains that are capable of binding specifically to ligands in the same way as their much larger counterparts, antibodies. Ligands of therapeutic interest that can be targeted are other peptide chains or loops located
Roger R. C. New, Tam T. T. Bui, Michal Bogus   +2 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source